Oct 2026· Frontiers in Pharmacology· Vol 17, pp.
1979177
· 0 citations· 60 references
Medicine
TL;DR
Findings suggest that SIN alleviates VaD-associated microglial dysfunction by modulating PCK1-associated immunometabolic alterations, and expands the current understanding of the pharmacological actions of SIN.
Abstract
Background
Vascular dementia (VaD) is one of the major causes of cognitive impairment among older adults. However, effective treatments that can modify the progression of the disease are still lacking. Emerging evidence indicates that metabolic remodeling in microglia influences inflammatory responses during vascular brain injury. Microglial immunometabolic regulation has therefore been proposed as an important contributor to the pathogenesis of vascular dementia (VaD).
Methods
Transcriptomic integration, WGCNA, network pharmacology, and single-nucleus RNA sequencing were combined to identify disease-associated microglial alterations and potential targets involved in sinomenine (SIN)-mediated regulation. The interaction between SIN and phosphoenolpyruvate carboxykinase 1 (PCK1) was investigated using molecular docking and molecular dynamics simulations. The biological effects of SIN were then validated in lipopolysaccharide (LPS)-stimulated BV2 microglia.
Results
Integrated analyses highlighted PCK1 as a potential mediator associated with SIN-induced metabolic regulation in VaD. snRNA-seq demonstrated expansion of metabolically stressed microglial states accompanied by PCK1-related metabolic alterations. Stable binding between SIN and PCK1 was supported by molecular docking and molecular dynamics simulations. In LPS-stimulated BV2 microglia, SIN suppressed inflammatory activation, restored PCK1 expression, attenuated inflammation-associated metabolic remodeling, improved cellular bioenergetics, and modulated metabolic redox-related parameters. SIN also enhanced adaptive stress responses through regulation of CRYAB, APOD, and HSPH1.
Conclusion
Collectively, these findings suggest that SIN alleviates VaD-associated microglial dysfunction by modulating PCK1-associated immunometabolic alterations. They expand the current understanding of the pharmacological actions of SIN and highlight microglial immunometabolic regulation as a potential therapeutic target for VaD.
Abstract Introduction Vascular dementia (VaD) is characterized by neurovascular unit dysfunction and neuroinflammation. However, the molecular regulators linking microglial activation to remodeling of intercellular communication remain incompletely understood. Methods The human postmortem single-nucleus RNA-sequencing...
Jia-Ni Hao, Song Luo, Li Li et al.· International Journal of Neu...· 0 citations
Alzheimer’s disease (AD) represents a progressive neurodegenerative disorder that predominantly impairs the central nervous system. This study integrated single-cell RNA sequencing (scRNA-seq) and Mendelian randomization (MR) analysis to explore AD therapeutic targets and characterize alterations in immune cell infiltr...
Wan-Qian Xu, Min Liu, Xia-Jing Yu et al.· Neurotherapeutics· 0 citations
Background Neuroinflammation, particularly involving reactive astrocytes, plays a pivotal role in Alzheimer's disease (AD) progression. Objective However, the causal genes and regulatory pathways linking astrocyte reactivity to AD risk remain unclear. Methods We performed a multi-omics summary-data-based Mendelian rand...
Depressive disorder (DD) is recognized as an important comorbidity of Alzheimer's disease (AD) and is associated with aggravated cognitive impairment and neuroinflammatory responses; however, the underlying molecular mechanisms remain largely unknown. This study investigated the role of the Sirtuin 1 (Sirt1)/p53 acetyl...
Fang-Xian Chai, Shan Qing, Yong-Xue Hu et al.· Brain Research Bulletin· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.